Shield Therapeutics’ iron deficiency drug Feraccru has been accepted for review by the US Food and Drug Administration (FDA). Shield Therapeutics’ iron deficiency drug Feraccru has been accepted for ...

Oral iron replacement therapy Feraccru has been shown to have comparable efficacy to intravenously delivered Ferinject in patients with Iron Deficiency Anaemia, offering a "real" alternative to ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Feraccru" drug pipelines has been added to ResearchAndMarkets.com's offering. Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) ...

Feraccru, a novel, effective and well tolerated treatment for iron deficiency (ID) with or without anaemia including treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD), is ...

The data demonstrate that Feraccru is non-inferior to the market-leading IV iron (Ferinject) and has triggered a €2.5m payment from its marketing partner Norgine. Additional near-term revenue ...

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, is pleased to note the ...

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

LONDON – Shield Therapeutics plc is "back in control of its own destiny" after securing an immediate £11 million (US$14.5 million) payment as part of an exclusive commercialization agreement for its ...

LONDON (Alliance News) - Pharmaceutical company Shield Therapeutics PLC on Friday said it has seen "very encouraging" signals of demand for its Feraccru product in the six months since launching in ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A Newcastle-based pharmaceuticals company is planning to raise up to £110m in a flotation on the London Stock ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". LONDON, December 5, 2018 /PRNewswire/ -- Feraccru®, a novel, effective and ...